Andre H. Goy, MD

Articles

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

May 6th 2024

Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.

Dr. Goy on Durable Responses With Brexu-cel in the ZUMA-2 Trial in MCL

February 13th 2023

Andre H. Goy, MD, discusses key findings from an assessment of durable responses in the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Dr. Goy on the Clinical Implications of Treating Indolent MCL

November 15th 2022

Andre H. Goy, MD, discusses the clinical implications of treating indolent mantle cell lymphoma.

Dr. Goy on Discrepancies in Clinical Trial vs Real-World MCL Treatment

October 17th 2022

Andre H. Goy, MD, discusses clinical trial vs real-world treatments in patients with mantle cell lymphoma.

Inside the Clinic: Experts Explore Case Studies in DLBCL

May 16th 2022

Maher Albitar, MD, and Andre H. Goy, MD, discuss case studies in diffuse large B-cell lymphoma.

Inside the Clinic: Experts Discuss Testing for Molecular Abnormalities in AML

May 13th 2022

Maher Albitar, MD, and Andre H. Goy, MD, discuss the importance of testing for molecular abnormalities in acute myeloid leukemia.

Inside the Clinic: Experts Highlight Molecular Complexities in MCL

May 13th 2022

Maher Albitar, MD, and Andre H. Goy, MD, share insights regarding molecular complexities in mantle cell lymphoma.

Inside the Clinic: Experts Discuss Practical Aspects of Next-Generation Sequencing

May 12th 2022

Maher Albitar, MD, and Andre H. Goy, MD, discuss practical aspects of next-generation sequencing.

Inside the Clinic: JTCC Experts Share Strategies for When CAR T-Cell Therapy Is Not an Option

March 15th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, share strategies for when CAR T-cell therapy is not an option.

Inside the Clinic: JTCC Experts Discuss Approaches to CAR T-Cell Therapy

March 15th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss approaches to CAR T-cell therapy.

Inside the Clinic: JTCC Experts Highlight Optimal Strategies for CAR T-Cell–Related AEs

March 10th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss optimal strategies for CAR T-cell–related adverse effects.

Inside the Clinic: JTCC Experts Discuss Retreatment With CAR T-Cell Therapy

March 10th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss retreatment with CAR T-cell therapy.

Inside the Clinic: JTCC Experts Highlight Next Steps With CAR T-Cell Therapy

March 9th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.

Dr. Goy on the Utility of Axi-Cel and Brexu-Cel in Relapsed/Refractory Non-Hodgkin Lymphoma

January 10th 2022

Andre H. Goy, MD, discusses the clinical data reported with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma and real-world findings with brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Goy on the Clinical Implications of CAR T-Cell Therapy in MCL

April 8th 2021

Andre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.

Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

May 10th 2020

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.